Evidence map›Paper›PMID 40919955›Full record

ArticleMicrobiology spectrum2025

Viral viability markers of SARS-CoV-2: a comparison of cell culture, genomic RNA RT-PCR, and subgenomic RNA RT-PCR.

Genoveva Cuesta-Chasco, Francesco Tommaso Aiello, Cristina Rodriguez, Anna Villasante, Juan Carlos Hurtado, Francesc Fernández Avilés, Luis Gerardo Rodríguez-Lobato, Mireia Navarro, Ignacio Grafia, Marta Bodro and 3 more

Abstract readComparative Study
In one paragraph

Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Genoveva Cuesta-ChascoDepartment of Clinical Microbiology, Hospital Clínic of Barcelona-ISGlobal, University of Barcelona, Barcelona, Spain.ORCID 0000-0002-9031-0787
Francesco Tommaso AielloDepartment of Infectious Diseases, Hospital Clínic of Barcelona-IDIBAPS, University of Barcelona, Barcelona, Spain.ORCID 0000-0003-4441-6318
Cristina RodriguezDepartment of Clinical Microbiology, Hospital Clínic of Barcelona-ISGlobal, University of Barcelona, Barcelona, Spain.
Anna VillasanteDepartment of Clinical Microbiology, Hospital Clínic of Barcelona-ISGlobal, University of Barcelona, Barcelona, Spain.
Juan Carlos HurtadoDepartment of Clinical Microbiology, Hospital Clínic of Barcelona-ISGlobal, University of Barcelona, Barcelona, Spain.
Francesc Fernández AvilésDepartment of Hematology, Hospital Clínic of Barcelona-IDIBAPS, University of Barcelona, Barcelona, Spain.
Luis Gerardo Rodríguez-LobatoDepartment of Hematology, Hospital Clínic of Barcelona-IDIBAPS, University of Barcelona, Barcelona, Spain.
Mireia NavarroDepartment of Clinical Microbiology, Hospital Clínic of Barcelona-ISGlobal, University of Barcelona, Barcelona, Spain.
Ignacio GrafiaDepartment of Oncology, Hospital Clínic of Barcelona-IDIBAPS, University of Barcelona, Barcelona, Spain.
Marta BodroDepartment of Infectious Diseases, Hospital Clínic of Barcelona-IDIBAPS, University of Barcelona, Barcelona, Spain.ORCID 0000-0002-0520-8279
Carolina García-VidalDepartment of Infectious Diseases, Hospital Clínic of Barcelona-IDIBAPS, University of Barcelona, Barcelona, Spain.ORCID 0000-0002-8915-0683
Alex Soriano *Department of Infectious Diseases, Hospital Clínic of Barcelona-IDIBAPS, University of Barcelona, Barcelona, Spain.
Maria Angeles Marcos *Department of Clinical Microbiology, Hospital Clínic of Barcelona-ISGlobal, University of Barcelona, Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accurate methods to assess viral viability are crucial for determining isolation duration and antiviral therapy in immunocompromised patients. Although cell culture (CC) is the gold standard, it has limitations. Cycle threshold (Ct) values from genomic RNA (gRNA) RT-PCR and subgenomic RNA (sgRNA) RT-PCR have been proposed as markers of active viral replication. This study evaluated the correlation between CC, gRNA Ct values, and sgRNA to identify the best viral viability marker. This study aimed to evaluate the correlation between CC, gRNA Ct values, and sgRNA to identify the best viral viability marker. We conducted a prospective study on immunocompromised patients with suspected SARS-CoV-2 infection at a tertiary hospital (May 2021 to May 2023). Nasopharyngeal swabs were inoculated into Vero E6 cells and tested for gRNA using RT-PCR (Cobas 6800, Roche) and for sgRNA (non-commercial RT-PCR). The sensitivity (S), specificity (SP), positive (PPV) and negative predictive value (NPV), and accuracy were calculated using CC as the gold standard. Among 285 samples from 108 patients, gRNA RT-PCR had high S and NPV (1.0) but low SP (0.24) and moderate PPV (0.63). Ct analysis improved performance in extreme but not intermediate values. A Ct ≤ 30 maximized S but had low SP; Ct ≤ 25 yielded S (0.88), SP (0.89), PPV (0.92), NPV (0.84), and accuracy (0.88); sgRNA showed the highest S (0.99), SP (0.96), PPV (0.97), NPV (0.99), and accuracy (0.98). sgRNA detection is the best marker for identifying viable SARS-CoV-2, aiding decisions on isolation, antiviral treatment, or delaying chemotherapy in immunocompromised patients. IMPORTANCE: Identifying whether a patient still has contagious SARS-CoV-2 is essential for managing isolation, antiviral treatment, and other clinical decisions-especially in immunocompromised individuals. While viral culture is the gold standard for confirming viral viability, it is slow, expensive, and not widely available. Many hospitals rely on RT-PCR tests, but these detect viral genetic material whether or not the virus is still active. This study shows that detecting subgenomic RNA (sgRNA), a molecule only present when the virus is actively replicating, is a highly accurate way, a molecule only present when the virus is actively replicating, is a highly accurate way to determine whether the virus is still viable. Compared to standard PCR or viral culture, sgRNA testing better predicts who is truly infectious. These findings support sgRNA as a useful tool to guide clinical management and infection control in vulnerable patients.

Indexed as

COVID-19Microbial ViabilityReverse Transcriptase Polymerase Chain ReactionRNA, ViralSARS-CoV-2AdultAgedAnimalsCell Culture TechniquesChlorocebus aethiopsCOVID-19 Nucleic Acid TestingFemaleGenome, ViralHumansImmunocompromised HostMaleRNA, ViralSubgenomic RNASARS-CoV-2subgenomic RNAsurrogate markers of active viral replication

Identifiers

PMID40919955
PMCPMC12502786

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.